相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations
Elie Traer et al.
BLOOD (2014)
A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia
Leyuan Ma et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12
Anup Kumar Singh et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2013)
Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous Leukemia
Bin Zhang et al.
CANCER CELL (2012)
Rottlerin enhances IL-1β-induced COX-2 expression through sustained p38 MAPK activation in MDA-MB-231 human breast cancer cells
Eun Jung Park et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2011)
PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice
Cong Peng et al.
BLOOD (2010)
The Chemokine Receptor CXCR7 Is Highly Expressed in Human Glioma Cells and Mediates Antiapoptotic Effects
Kirsten Hattermann et al.
CANCER RESEARCH (2010)
Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein
Marcus Jaras et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Imatinib resistance in multidrug-resistant K562 human leukemic cells
Yanina Assef et al.
LEUKEMIA RESEARCH (2009)
Cytokines as a key component of cancer-related inflammation
Giovanni Germano et al.
CYTOKINE (2008)
Bcr-abl-independent imatinib-resistant k562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors
Sang Min Lee et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia
Ellen Weisberg et al.
NATURE REVIEWS CANCER (2007)
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib
Ian J. Griswold et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance
Mateusz Koptyra et al.
BLOOD (2006)
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition
Hans-Guido Wendel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein
P Neviani et al.
CANCER CELL (2005)
Regulation of the C-Abl and Bcr-Abl tyrosine kinases
O Hantschel et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Role of cyclooxygenase-2 in the angiogenesis of colorectal cancer
M Rao et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2004)
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
TP Hughes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-α
J Cortes et al.
BLOOD (2003)
Philadelphia chromosome-positive leukemias: From basic mechanisms to molecular therapeutics
R Kurzrock et al.
ANNALS OF INTERNAL MEDICINE (2003)
IL-1 is required for tumor invasiveness and angiogenesis
E Voronov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The balance between IL-1 and IL-1Ra in disease
WR Arend
CYTOKINE & GROWTH FACTOR REVIEWS (2002)
Role of the microenvironment in promoting angiogenesis in acute myeloid leukemia
C Litwin et al.
AMERICAN JOURNAL OF HEMATOLOGY (2002)
Many actions of cyclooxygenase-2 in cellular dynamics and in cancer
Y Cao et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2002)
Regulation of hematopoietic growth factor production by genetically modified human bone marrow stromal cells expressing interleukin-1β antisense RNA
UF Hartwig et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2001)
Bcr-Abl protein tyrosine kinase activity induces a loss of p53 protein that mediates a delay in myeloid differentiation
A Pierce et al.
ONCOGENE (2000)
分享论文
